account_id none on file
legal_name BioNTech SE
ticker BNTX
cik 1776985
domain biontech.com
linkedin_company_url https://www.linkedin.com/company/biontech-se/
entry_point_account_id none on file
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 60 executives 0 family 0
why_now
this year. Second, build momentum in combination therapy. In 2026, we are expanding our novel novel combination strategy centered around Pumitamic as potential next-generation IO backbone. This includes the first expected readouts of com
Aug 4, 2026 / receipt
callsnone on file
filings
Planned FY 2023 expenses and capex1
ir_statement / Aug 25, 2026 / receipt
= New strategic collaboration
ir_statement / Aug 8, 2026 / receipt
Multiple solid tumors
ir_statement / Aug 8, 2026 / receipt
Oncology Pipeline: Significant Progress and Expansion in 2022
ir_statement / Aug 8, 2026 / receipt
Phase 1 (5 First-in-Human)
ir_statement / Aug 8, 2026 / receipt
Dose expansion tested in multiple cancer types including:
ir_statement / Aug 8, 2026 / receipt
MoA Designed to Allow Higher Dosing & Longer Duration ofTreatmentwithONC-392
ir_statement / Aug 8, 2026 / receipt
Monotherapy RP2D: 10 mg/kg, Combination RP2D: 6 mg/kg
ir_statement / Aug 8, 2026 / receipt
Preliminary data demonstrated lower irAE rate than observed for comparable IO or IO-IO combinations
ir_statement / Aug 8, 2026 / receipt
Safety profile of ONC-392 allows for higher dosing and longer duration of treatment in monotherapy and in combination with pembrolizumab
ir_statement / Aug 8, 2026 / receipt
= Label expansion//product launch
ir_statement / Aug 8, 2026 / receipt
10+ other infectious disease programs
ir_statement / Aug 8, 2026 / receipt
executivesnone on file
familynone on file
upcoming
changesnone on file
mcp_package_hint
slug biontech-se
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$